Video

Dr. Khong on the Potential Benefit of IO/Endocrine Therapy in ER+ Breast Cancer

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Hung Khong, MD, a breast oncologist within the Chemical Biology and Molecular Medicine Program at Moffitt Cancer Center, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor (ER)–positive, HER2-negative breast cancer.

ER-positive breast cancer is thought to be less aggressive compared with HER2-positive breast cancer and triple-negative breast cancer (TNBC), Khong explains.

However, ER-positive breast cancer is associated with a longer risk of recurrence versus HER2-positive or, in particular, TNBC, Khong adds.

If patients with TNBC have not recurred after 5 years, it is rare that recurrence will occur. Conversely, patients with ER-positive disease have a steady risk of relapse up to 30 years after diagnosis, says Khong.

As such, combining immunotherapy with endocrine therapy may offer patients with ER-positive disease long-term disease control, concludes Khong.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS